Media
Follow our progress and stay up to date with our press releases and media coverage.
Press Releases
GeneVentiv to Attend BIO Investor Forum
October 2, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO Investor Forum, which will be held in San Francisco, CA from October 17-18,...
GeneVentiv Wins Startup Spotlight Pitch Competition at BioPharm USA 2023
September 14, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company developing the first universal gene therapy for all types of hemophilia and the first for patients with inhibitors, today was announced...
GeneVentiv Invited to Present at BioPharm America 2023
August 30, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present at BioPharm AmericaTM, which will be held in Raleigh,...
GeneVentiv Welcomes New Advisors
August 29, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that it has added Robert Baffi and Deborah Wild as Advisors as the Company prepares...
GeneVentiv to Attend BIO International 2023
May 3, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend BIO International 2023, which will be held in Boston, MA from June 5-8, 2023. ...
GeneVentiv Invited to Present in Labcorp’s Symposium at the 26th Annual Meeting of the American Society of Cell and Gene Therapy
April 12, 2023 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced it has been invited to present as part of Labcorp’s symposium at the 26th Annual...
In the News
GeneVentiv Therapeutics selected to pitch at CED’s Venture Connect
https://wraltechwire.com/2022/03/07/startup-spotlight-presenting-companies-to-pitch-at-ceds-venture-connect/
Startup Spotlight: UNC-linked startup is giving hope to those with hemophilia
by Shellie Edge, Innovate Carolina — February 8, 2022 . Editor’s note: Startup Spotlight is a regular weekly feature in WRAL TechWire. This week’s feature comes from UNC-Chapel Hill’s Innovate Carolina. +++ CHAPEL HILL – For most people, a small cut on the hand or...
Universal hope for hemophilia
Universal hope for hemophilia Current hemophilia treatments have limitations for a significant number of patients. That’s why UNC-connected startup GeneVentiv Therapeutics is developing the first universal, single-dose gene therapy for all types of hemophilia,...
Potential Gene Therapy GENV-HEM Earns Orphan Drug Status
Hemophilia News Today by Marta Figueiredo PhD | November 3, 2021 The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to GENV-HEM, GeneVentiv Therapeutics’ investigational gene therapy for hemophilia A and B patients, with or without...
100+ companies will participate in CED’s Venture Connect – here’s who made the cut
by WRAL TechWire — January 29, 2021 RESEARCH TRIANGLE PARK – More than 100 startups and emerging entrepreneurial companies will participate in the Venture Connect 2021 summit, the Council for Entrepreneurial Development announced today. The event is set for March...
UNC Gene Therapy Spinoff Aims to Cure Hemophilia
Latest spinoff from UNC’s Gene Therapy Center wants to find a cure for hemophilia Read more here: https://www.newsobserver.com/news/business/article247379109.html#storylink=cpy RALEIGH UNC-Chapel Hill’s gene therapy center has birthed yet another startup in the...
New UNC spin-out targets hemophilia cure through gene therapy
By Seth Thomas Gulledge – Staff Writer, Triangle Business Journal - November 4, 2020 Companies in this article: University of North Carolina at Chapel Hill https://www.unc.edu/, GeneVentiv Therapeutics https:/www.geneventiv.com A new company launching around...
Raleigh’s GeneVentiv Therapeutics signs deal with UNC for potential hemophilia therapy
by Meredith Dockery, North Carolina Business News Wire — November 4, 2020 . RALEIGH — GeneVentiv Therapeutics, Inc., a gene therapy developer, announced a license agreement with the University of North Carolina at Chapel Hill for a patent-pending, gene therapy for...
UNC Spinout GeneVentiv’s Gene Therapy offers a Universal Cure for Hemophilia
November 2, 2020 RALEIGH, NC – GeneVentiv Therapeutics has entered a license agreement with University of North Carolina Chapel Hill for a gene therapy that is a universal cure for Hemophilia A or B patients with or without inhibitors to their missing clotting...